GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sunshine Biopharma Inc (NAS:SBFM) » Definitions » Cash Flow from Investing

Sunshine Biopharma (Sunshine Biopharma) Cash Flow from Investing : $-1.18 Mil (TTM As of Mar. 2024)


View and export this data going back to 2007. Start your Free Trial

What is Sunshine Biopharma Cash Flow from Investing?

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

For the three months ended in Mar. 2024, Sunshine Biopharma spent $0.06 Mil on purchasing property, plant, equipment. It gained $0.03 Mil from selling property, plant, and equipment. It spent $0.00 Mil on purchasing business. It gained $0.00 Mil from selling business. It spent $0.00 Mil on purchasing investments. It gained $0.00 Mil from selling investments. It paid $0.64Mil for net Intangibles purchase and sale. And it paid $0.00 Mil for other investing activities. In all, Sunshine Biopharma spent $0.67 Mil on investment activities in financial market and operating subsidiaries for the three months ended in Mar. 2024.


Sunshine Biopharma Cash Flow from Investing Historical Data

The historical data trend for Sunshine Biopharma's Cash Flow from Investing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sunshine Biopharma Cash Flow from Investing Chart

Sunshine Biopharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Investing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.02 - - -14.62 -0.66

Sunshine Biopharma Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Flow from Investing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.15 -0.26 0.02 -0.27 -0.67

Sunshine Biopharma Cash Flow from Investing Calculation

Cash Flow from Investing covers the cash a company gains or spends from investment activities in financial market and operating subsidiaries. It also includes the cash the company used for property, plant and equipment (PPE).

If a company spends cash on property, plant and equipment (PPE), this will reduce their cash position. This is called Capital Expenditures (CPEX).

Likewise, if a company buys another company for cash, this will reduce their cash position.

Sunshine Biopharma's Cash Flow from Investing for the fiscal year that ended in Dec. 2023 is calculated as:

Sunshine Biopharma's Cash Flow from Investing for the quarter that ended in Mar. 2024 is calculated as:


Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.18 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Sunshine Biopharma  (NAS:SBFM) Cash Flow from Investing Explanation

Cash flow from investing contains nine items:

1. Purchase Of Property, Plant, Equipment:
Purchase of PPE indicates the amount used to purchase property, plant, and equipment.

Sunshine Biopharma's purchase of property, plant, equipment for the three months ended in Mar. 2024 was $-0.06 Mil. It means Sunshine Biopharma spent $0.06 Mil on purchasing property, plant, equipment.

In the capital spending for property, plant and equipment (PPE), some part of spending may be from the expansion of business. The business needs more property, plant and equipment (PPE) as it grows. Another part may be from replacement of the property, plant and equipment (PPE) of existing business. For some companies, the cash spent on replacing of the property, plant and equipment (PPE) of the existing business will be close to the depreciation of property, plant and equipment (PPE) reported in the income statement.

In Warren Buffett's definition of Owner's Earnings, he deducts the estimate of the cost of replacing the property, plant and equipment (PPE) of the existing business from cash flow from operations. The cash spent on the new property, plant, and equipment is not deducted. The reason is because these are not costs of the existing business. In his 1986 letter to shareholders, Warren Buffett wrote this about owner earnings:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume....Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

2. Sale Of Property, Plant, Equipment:
Sale of PPE indicates the amount gained from selling property, plant, and equipment.

Sunshine Biopharma's sale of property, plant, equipment for the three months ended in Mar. 2024 was $0.03 Mil. It means Sunshine Biopharma gained $0.03 Mil from selling property, plant, and equipment.

3.Purchase Of Business:
Purchase of business indicates the amount used to purchase business.

Sunshine Biopharma's purchase of business for the three months ended in Mar. 2024 was $0.00 Mil. It means Sunshine Biopharma spent $0.00 Mil on purchasing business.

4. Sale Of Business:
Sale of business indicates the amount gained from selling business.

Sunshine Biopharma's sale of business for the three months ended in Mar. 2024 was $0.00 Mil. It means Sunshine Biopharma gained $0.00 Mil from selling business.

5. Purchase Of Investment:
Purchase of Investments represents cash outflow on the purchase of investments in securities.

Sunshine Biopharma's purchase of investment for the three months ended in Mar. 2024 was $0.00 Mil. It means Sunshine Biopharma spent {stock_data.stock.currency_symbol}}0.00 Mil on purchasing investments.

6. Sale Of Investment:
Sale of Investments represents cash inflow on the sale of investments in securities.

Sunshine Biopharma's sale of investment for the three months ended in Mar. 2024 was $0.00 Mil. It means Sunshine Biopharma gained $0.00 Mil from selling investments.

7. Net Intangibles Purchase And Sale:
Net Intangibles purchase and sale means the net cash inflow received by a company that comes from the purchase and sale of intangibles. It equals the cash received from sale of intangibles minus the cash spent on purchasing intangibles.

Sunshine Biopharma's net Intangibles purchase and sale for the three months ended in Mar. 2024 was $-0.64 Mil. It means Sunshine Biopharma paid $0.64 Mil for net Intangibles purchase and sale.

8. Cash From Discontinued Investing Activities:
Cash from discontinued investing activities means the cash received by a company that comes from the discontinued investing activities.

Sunshine Biopharma's cash from discontinued investing activities for the three months ended in Mar. 2024 was 0.00 Mil. It means Sunshine Biopharma paid $0.00 Mil for discontinued investing activities.

9. Cash From Other Investing Activities:
Cash from other investing activities means the cash received by a company that comes from other investing activities.

Sunshine Biopharma's cash from other investing activities for the three months ended in Mar. 2024 was $-0.00 Mil. It means Sunshine Biopharma paid $0.00 Mil for other investing activities.


Sunshine Biopharma Cash Flow from Investing Related Terms

Thank you for viewing the detailed overview of Sunshine Biopharma's Cash Flow from Investing provided by GuruFocus.com. Please click on the following links to see related term pages.


Sunshine Biopharma (Sunshine Biopharma) Business Description

Traded in Other Exchanges
N/A
Address
6500 Trans-Canada Highway, 4th Floor, Pointe-Claire, QC, CAN, H9R 0A5
Sunshine Biopharma Inc is a pharmaceutical company focused on the research, development, and commercialization of oncology and antiviral drugs. In addition, it is engaged in the development and commercialization of science-based nutritional supplements. The company is focusing on the development of the licensed Adva-27a anticancer drug, a small molecule that has been shown to be exceptionally effective at destroying Multidrug-Resistant Cancer Cells, including Pancreatic Cancer cells (Panc-1), Small-Cell Lung Cancer cells (H69AR), Breast Cancer cells (MCF-7/MDR) and Uterine Sarcoma cells (MES-SA/Dx5).
Executives
Camille Sebaaly director, officer: CFO and Secretary 14464 GOUIN W., #B, MONTREAL A8 H9H 1B1
Malek Chamoun 10 percent owner 1730 RUE SAINT-PATRICK UNIT 601, MONTREAL Z4 H3K0B2
David Natan director 11190 BISCAYNE BLVD, MIAMI FL 33181
Andrew Mark Keller director 10 ISLAND DRIVE, NORWALK CT 06855
Andrew I Telsey director 6198 SOUTH MOLINE COURT, ENGLEWOOD CO 80111
James Daniel Kish director 6456 S QUEBEC ST., SUITE 550, CENTENNIAL CO 80111
Rabi Kiderchah director 924 PIERRE-DANSEREAU AVE, APT 206, TERREBONNE A8 J6Y 0N3
Advanomics Corp 10 percent owner 579 RUE LAJEUNESSE, LAVAL A8 H7X 3K4
Steve N. Slilaty director, 10 percent owner, officer: CEO and President 579 RUE LAJEUNESSE, LAVAL A8 H7X 3K4
Abderrazzak Merzouki director, officer: Chief Operating Officer 731 PLACE DE L'EEAU VIVE, LAVAL A8 H7Y 2E1
Turi Michele Di director, officer: Chief Operating Officer 3100 BOUL. DES GOUVERNEURS, LAVAL A8 H7E 5J3

Sunshine Biopharma (Sunshine Biopharma) Headlines

From GuruFocus

Sunshine Biopharma Files Its Second Quarter Report With the SEC

By PurpleRose PurpleRose 08-04-2022